Merus (MRUS) Raised to “Hold” at BidaskClub

BidaskClub upgraded shares of Merus (NASDAQ:MRUS) from a sell rating to a hold rating in a report released on Saturday, BidAskClub reports.

A number of other brokerages have also weighed in on MRUS. Zacks Investment Research upgraded Merus from a hold rating to a buy rating and set a $15.00 price objective for the company in a research note on Friday, March 15th. Citigroup reduced their target price on Merus from $18.00 to $16.00 and set a neutral rating on the stock in a report on Friday, March 15th. Royal Bank of Canada raised Merus from a sector perform rating to an outperform rating and increased their target price for the stock from $18.00 to $23.00 in a report on Wednesday, April 3rd. Guggenheim initiated coverage on Merus in a report on Friday. They set a buy rating and a $25.00 target price on the stock. Finally, ValuEngine downgraded Merus from a hold rating to a sell rating in a report on Monday, February 4th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $23.00.

Shares of NASDAQ MRUS opened at $16.45 on Friday. Merus has a fifty-two week low of $11.00 and a fifty-two week high of $26.74. The company has a market cap of $349.21 million, a price-to-earnings ratio of -8.94 and a beta of -0.06.

A number of large investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC lifted its holdings in Merus by 10.3% during the 4th quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock worth $165,000 after buying an additional 1,100 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Merus by 18.8% during the 4th quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock worth $209,000 after buying an additional 2,373 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Merus by 33.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 17,723 shares of the biotechnology company’s stock worth $350,000 after buying an additional 4,476 shares during the last quarter. Morgan Stanley lifted its holdings in Merus by 74.3% during the 3rd quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock worth $1,415,000 after buying an additional 30,538 shares during the last quarter. Finally, Aquilo Capital Management LLC lifted its holdings in Merus by 3.6% during the 3rd quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock worth $25,577,000 after buying an additional 44,799 shares during the last quarter. 53.06% of the stock is currently owned by institutional investors.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

See Also: How to invest in a bear market

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.